NSCLC

[JCI Insight] Scientists identified the senescence-like characteristics of cancer-associated fibroblasts (CAFs) after RT and clarify the formidable ability of senescence-like CAFs in promoting NSCLC cell proliferation and radioresistance through the JAK/STAT pathway.

[Checkpoint Therapeutics. Inc. (GlobenewsWire, Inc.)] Checkpoint Therapeutics, Inc. announced the initiation of the CONTERNO study, a global, randomized Phase III trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer.

[Environmental Toxicology] Researchers found that RNF168 expression was positively correlated with the overall survival, first-progression survival, and postprogression survival of lung adenocarcinoma, but not correlated with these survivals of squamous cell carcinoma of lung.

[Scientific Reports] In vitro experimentas focused on the anti-lung adenocarcinoma (LUAD) effects and mechanisms of Tanshinone IIA on LUAD cells via MTT, plate cloning, Annexin V-FITC and PI dual staining, flow cytometry, and western blot assays.

[Experimental & Molecular Medicine] The authors reported that BIX01294 (BIX) induced apoptotic cell death in EGFR-mutant NSCLC cells but not in their wild-type counterparts. Treatment with BIX resulted in a significant reduction in the EGFR level and inhibition of EGFR signaling only in EGFR-mutant NSCLC cells, leading to apoptosis.

[npj Precision Oncology] Investigators utilized 343 longitudinal plasma DNA samples from 43 ALK alterations NSCLC patients receiving ALK-directed therapies to determine molecular progression based on matched panel-based targeted next-generation sequencing, and shallow whole-genome sequencing.